P Correale

Summary

Affiliation: University of Siena
Country: Italy

Publications

  1. ncbi request reprint 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine
    Pierpaolo Correale
    Siena University School of Medicine, Viale Bracci 1, 53100 Siena, Italy
    J Natl Cancer Inst 97:1437-45. 2005
  2. pmc Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation
    P Correale
    Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
    Br J Cancer 96:1343-7. 2007
  3. pmc Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy
    Salvatore P Prete
    Department of Neuroscience, Section of Pharmacology and Medical Oncology, University of Rome, Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
    J Exp Clin Cancer Res 27:5. 2008
  4. doi request reprint Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs
    Pierpaolo Correale
    Medical Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Italy
    J Immunother 31:132-47. 2008
  5. ncbi request reprint Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer
    Pierpaolo Correale
    Section of Medical Oncology, Human Pathology and Oncology Department, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
    Cancer Chemother Pharmacol 56:563-8. 2005
  6. ncbi request reprint Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer
    P Correale
    Medical Oncology Division, Department of Human Pathology and Oncology, Siena University School of Medicine, Italy
    J Chemother 20:119-25. 2008
  7. ncbi request reprint A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients
    P Correale
    Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, I 53100 Siena, Italy
    Oncol Rep 16:133-40. 2006
  8. ncbi request reprint Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
    Pierpaolo Correale
    Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
    J Immunol 175:820-8. 2005
  9. pmc UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
    R Petrioli
    Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
    Br J Cancer 90:306-9. 2004
  10. ncbi request reprint Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes
    P Correale
    Medical Oncology Division, Medicine School, Siena University, 53100, Siena, Italy
    Eur J Cancer 37:2097-103. 2001

Collaborators

Detail Information

Publications46

  1. ncbi request reprint 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine
    Pierpaolo Correale
    Siena University School of Medicine, Viale Bracci 1, 53100 Siena, Italy
    J Natl Cancer Inst 97:1437-45. 2005
    ..01 could induce a TS-directed cytotoxic T-lymphocyte (CTL) response with antitumor activity...
  2. pmc Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation
    P Correale
    Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
    Br J Cancer 96:1343-7. 2007
    ..The average time to progression and to survival were 9 and 24 months respectively. These results suggest that this chemo-hormone therapy regimen is well tolerated and active in patients with non-well differentiated endocrine tumours...
  3. pmc Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy
    Salvatore P Prete
    Department of Neuroscience, Section of Pharmacology and Medical Oncology, University of Rome, Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
    J Exp Clin Cancer Res 27:5. 2008
    ..Thus, we investigated whether FUL in combination with OXA according to 2 different schedules may influence CEA expression in human colon cancer cells in vitro...
  4. doi request reprint Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs
    Pierpaolo Correale
    Medical Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Italy
    J Immunother 31:132-47. 2008
    ..These results may have clinical implications for the design of new translational anticancer regimens aimed at combining chemotherapy and immunotherapy...
  5. ncbi request reprint Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer
    Pierpaolo Correale
    Section of Medical Oncology, Human Pathology and Oncology Department, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
    Cancer Chemother Pharmacol 56:563-8. 2005
    ..We have therefore designed a multi-center phase II trial in order to test a novel GEM+FOLFOX-4 regimen in patients with metastatic gastric cancer...
  6. ncbi request reprint Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer
    P Correale
    Medical Oncology Division, Department of Human Pathology and Oncology, Siena University School of Medicine, Italy
    J Chemother 20:119-25. 2008
    ..5 and 8 months, respectively. In conclusion, the GOLF regimen appears to be a feasible treatment for patients with advanced pancreatic carcinoma that deserves to be evaluated in phase III trials...
  7. ncbi request reprint A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients
    P Correale
    Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, I 53100 Siena, Italy
    Oncol Rep 16:133-40. 2006
    ..These preliminary results indicate that our metronomic regimen is well tolerated and active, even in patients with a very poor prognosis...
  8. ncbi request reprint Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
    Pierpaolo Correale
    Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
    J Immunol 175:820-8. 2005
    ....
  9. pmc UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
    R Petrioli
    Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
    Br J Cancer 90:306-9. 2004
    ..There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC...
  10. ncbi request reprint Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes
    P Correale
    Medical Oncology Division, Medicine School, Siena University, 53100, Siena, Italy
    Eur J Cancer 37:2097-103. 2001
    ..These results provide a rationale for investigating GC90V in clinical trials of anticancer vaccine therapy...
  11. ncbi request reprint Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies
    P Correale
    Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Siena, Italy
    J Chemother 16:206-10. 2004
    ..We therefore believe that an improved version would merit further investigation in larger scale trials...
  12. ncbi request reprint Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients
    P Correale
    Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
    Eur J Cancer 39:1547-51. 2003
    ..Our finding may be useful in designing future studies of the combination in order to reduce the occurrence of side-effects and to maximise the antitumour activity...
  13. pmc A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid
    P Correale
    Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
    Br J Cancer 89:239-42. 2003
    ..10 months (95% CI 9.64-16.56). There were seven cases of each grade III gastroenteric and haematological toxicity. The GEM plus FUFA combination appears to be well tolerated and very active in patients with pancreatic carcinoma...
  14. pmc A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma
    P Correale
    Section of Oncology, Human Pathology and Oncology Department, University of Siena School of Medicine, Viale Bracci 11, Siena 53100, Italy
    Br J Cancer 90:1710-4. 2004
    ..The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months. Our GOLF combination is well tolerated and seems promising for the treatment of advanced colorectal cancer...
  15. ncbi request reprint Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate
    A Licchetta
    Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
    J Chemother 22:201-4. 2010
    ..0%, disease control rate 41.3%, mean time to tumor progression 7.4 months (CI 95%, 3.8-10.88, range 1-48 months) and mean overall survival 13.4 months (CI 95%, 7.24-17.18, range 1-53 months). The mCM regimen was active and well tolerated...
  16. ncbi request reprint Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer
    Pierpaolo Correale
    Section of Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
    J Clin Oncol 23:8950-8. 2005
    ..This provides the rationale for combining chemo- and immunotherapy...
  17. ncbi request reprint Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen
    P Correale
    Section of Medical Oncology, Department of Clinical Medicine and Immunological Sciences, Siena University School of Medicine, Siena, Italy
    J Chemother 20:278-81. 2008
    ..In this manuscript we describe a clinical case concerning a patient with metastatic colon carcinoma who responded to the GOLFIG regimen, showed symptoms of autoimmunity [Discoid Lupus Erythematosus (DLE)] and had a very long survival...
  18. ncbi request reprint Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial
    P Correale
    Division of Medical Oncology, University of Siena, Viale Bracci 11, 53100, Siena, Italy
    Eur J Cancer 37:892-902. 2001
    ..Its biological activity may support tumour associated antigen (TAA)-specific anticancer immunotherapy by increasing antigen presenting cell (APC) activity and T cell immune competence in vivo...
  19. doi request reprint Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy
    Pierpaolo Correale
    Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
    J Immunother 33:435-41. 2010
    ..1 mo vs. 9.9 mo, P=0.01). Our results suggest that a higher FoxP3+ T-lymphocyte tumor infiltration score is a favorable prognostic factor in colon cancer patients undergoing chemo or chemoimmunotherapy...
  20. doi request reprint Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro
    P Correale
    Medical Oncology Unit, Department of Oncology, Siena University Hospital, Istituto Toscano Tumori, Siena, Italy
    Int J Cancer 130:1577-89. 2012
    ..On the basis of our data, we suggest a possible involvement of CTL-dependent immunity in cetuximab anti-cancer effects...
  21. ncbi request reprint Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma
    G Francini
    Medical Oncology Division, Institute of Internal Medicine, University of Siena, Siena, Italy
    Cancer 92:1468-74. 2001
    ....
  22. doi request reprint Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial)
    Pierpaolo Correale
    Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Rheumatology Unit, Siena University School of Medicine, Siena, Italy
    Clin Cancer Res 14:4192-9. 2008
    ..We have thus investigated the immunobiological feedback to the treatment and its possible correlation with the clinical outcome of these patients...
  23. doi request reprint Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine
    Pierpaolo Correale
    Department G Segre of Pharmacology, Medical Oncology Section, Department of Human Pathology and Oncology, University of Siena, Viale Bracci 11, 53100 Siena, Italy
    Cancer Lett 263:291-301. 2008
    ..01 amino acid binding motifs. This peptide is able to generate a human PTH-rP specific CTL response with anti-tumor activity in vitro and in mice...
  24. ncbi request reprint Immunological characterization of respiratory syncytial virus N protein epitopes recognized by human cytotoxic T lymphocytes
    Chiara Terrosi
    Microbiology Section, Department of Molecular Biology, University of Siena, Siena, Italy
    Viral Immunol 20:399-406. 2007
    ..N-RSV1 and N-RSV3 peptides elicited the strongest cytolytic activity against RSV-infected cells and they could be useful epitopes for the analysis of CTL responses to RSV and for understanding immune-induced disease pathogenesis...
  25. pmc Weekly epirubicin in patients with hormone-resistant prostate cancer
    R Petrioli
    Medical Oncology Division, Institute of Internal Medicine, University of Siena, Siena, Italy
    Br J Cancer 87:720-5. 2002
    ..Weekly epirubicin chemotherapy can lead to a rapid and lasting palliative result in patients with metastatic HRPC, and have a positive effect on the quality of life and survival...
  26. pmc In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse
    A Scardino
    INSERM U 487, IGR, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Br J Cancer 89:199-205. 2003
    ..The immune response capacity and the absence of any sign of toxicity and/or autoimmunity in vivo suggest the GC90/IRIV vaccine as a valid tool for active specific immunotherapy of human cancers and metastases overexpressing PTH-rP...
  27. ncbi request reprint Comparative study of the immune response in mice immunized with four live attenuated strains of mumps virus by intranasal or intramuscular route
    M G Cusi
    Department of Molecular Biology, University of Siena, Italy
    Arch Virol 146:1241-8. 2001
    ..Thus, the intranasal immunization could be considered a possible alternative and efficient route of vaccination against mumps...
  28. ncbi request reprint Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine
    Maria Grazia Cusi
    Virology Section, Department of Molecular Biology, Siena University School of Medicine, Italy
    J Immunol 174:7210-6. 2005
    ....
  29. ncbi request reprint Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens
    Guido Francini
    Institute of Internal Medicine, Medical Oncology Division, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, Italy
    Cancer Chemother Pharmacol 50:271-6. 2002
    ..To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens...
  30. ncbi request reprint High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects
    Guido Francini
    Division of Medical Oncology, Institut National de la Santé et de la Recherche Médicale Unité d Immunité Cellulaire Antivirale, Institut Pasteur, Paris, France
    J Immunol 169:4840-9. 2002
    ..In this study we describe two immunogenic and toxic-free PTH-rP peptides as valid candidates for the design of peptide-based vaccination strategies against prostate cancer and bone metastases from the most common epithelial malignancies...
  31. pmc Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects
    Maria Grazia Cusi
    Department of Molecular Biology, Microbiology Section, University School of Medicine, V, le Bracci, 1, 53100 Siena, Italy
    Immun Ageing 7:14. 2010
    ..Our finding also lays the basis for new therapeutic perspectives that could limit or prevent severe RSV infection in elderly...
  32. doi request reprint Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC)
    Pierpaolo Correale
    Translational Immuno Oncology Unit, Medical Oncology Section, Department G Segre of Pharmacology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
    Eur J Cancer 46:1703-11. 2010
    ..The results of our study suggest that chemotherapy may enhance cetuximab-mediated immuno-targeting and ADCC thus providing the rationale to design novel immuno-biochemotherapy regimens...
  33. ncbi request reprint Efficient delivery of DNA to dendritic cells mediated by influenza virosomes
    Maria Grazia Cusi
    Department of Molecular Biology, Microbiology Section, University of Siena, Via Laterina 8, 53100 Siena, Italy
    Vaccine 22:735-9. 2004
    ..These findings suggest that the virosome is an efficient delivery system for testing infectious, as well as anti-cancer, DNA-based vaccine research...
  34. ncbi request reprint Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients
    Pierpaolo Correale
    Translational Immuno Oncology Unit, Medical Oncology Section, Department G Segre of Pharmacology, Siena University School of Medicine, Siena, Italy
    Cancer Biol Ther 9:685-93. 2010
    ..We also evaluated the antitumor activity of this combination...
  35. ncbi request reprint Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases
    Roberto Petrioli
    Department of Human Pathology and Oncology, University of Siena, Siena, Italy
    Urology 63:321-6. 2004
    ..To investigate the prognostic value of some conventional bone markers and a number of other factors in terms of the survival of patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy...
  36. ncbi request reprint Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity
    M G Cusi
    Department of Molecular Biology, University of Siena, Via Laterina, 8 53100, Siena, Italy
    Vaccine 20:3436-42. 2002
    ..These results show that i.n. immunization of BALB/c mice with RSV-F/IRIV in combination with HLT can be considered a promising approach for the development of an efficacious human vaccine...
  37. ncbi request reprint Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens
    Roberto Petrioli
    Medical Oncology Division, Institute of Internal Medicine, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100, Siena, Italy
    Lung Cancer 39:85-9. 2003
    ..The aim of this study was to evaluate the activity and safety of weekly docetaxel treatment in patients with advanced NSCLC previously treated with two chemotherapy regimens...
  38. ncbi request reprint Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy
    Roberto Petrioli
    Medical Oncology Division, Institute of Internal Medicine, University of Siena, Siena, Italy
    Oncology 64:300-5. 2003
    ..The aim of this study was to evaluate the activity and tolerability of docetaxel in patients with hormone-resistant prostate cancer previously exposed to chemotherapy...
  39. ncbi request reprint Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma
    Roberto Petrioli
    Institute of Internal Medicine, Medical Oncology Division, University of Siena, Policlinico Le Scotte, Viale Bracci, 11, 53100, Siena, Italy
    Am J Clin Oncol 25:468-73. 2002
    ..06). The power of the study was 0.65 for both the DFI and overall survival. The results of the study suggest a possible advantage of epirubicin-based adjuvant chemotherapy in patients with soft-tissue sarcoma at high risk of relapse...
  40. ncbi request reprint Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2
    Pierpaolo Correale
    Interdipartimental Oncopharmacology Center, Faculty of Medicine, University of Siena, Viale Bracci 11, 53100 Siena, Italy
    Oncol Rep 13:751-6. 2005
    ..Our results suggest that this GM-CSF/hrIL-2 combination is active and well tolerated in patients with renal cell carcinoma and deserves to be investigated in larger comparative trials...
  41. ncbi request reprint Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases
    Daniela Cerretani
    Department of Pharmacology G Segre, University of Siena, Via delle Scotte 6, 53100 Siena, Italy
    Vascul Pharmacol 39:1-6. 2002
    ..001). 4. The reduction in AUC following HHMI explains the limited systemic toxicity in treated patients, with a greater total tumor exposure to the drug and improved drug activation...
  42. ncbi request reprint Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer
    Roberto Petrioli
    Department of Medical Oncology, University of Siena, Italy
    Hepatogastroenterology 52:1626-30. 2005
    ..The aim of this study was to evaluate the survival benefit of adjuvant chemotherapy with etoposide, leucovorin and 5-fluorouracil (ELF) in gastric cancer patients undergoing previous surgery with a curative intent...
  43. ncbi request reprint Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation
    Michele Caraglia
    Experimental Oncology Department, National Cancer Institute Fondazione G Pascale, Naples, Italy
    Cancer Biol Ther 4:1159-67. 2005
    ..These effects likely occurred through the disruption of critical survival pathways and the inactivation of multi-chaperone complex...
  44. ncbi request reprint Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro
    Pierpaolo Correale
    Oncopharmacology Center, School of Medicine, University of Siena, Italy
    Int J Cancer 104:437-45. 2003
    ..These results provide a rationale for investigating a possible new role of 5-FU as an immuno targeting amplifier agent in breast and colorectal cancer patients immunized with CEA-directed cancer vaccines...
  45. ncbi request reprint Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience
    Pierpaolo Correale
    Center of Oncopharmacological Research, Faculty of Medicine, University of Siena, Italy
    Invest New Drugs 24:99-110. 2006
    ..This report tries to review the possible rationale of the chemo-immunotherapy combination, illustrating preliminary results of preclinical and clinical studies...
  46. ncbi request reprint A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge
    Antonio Scardino
    Institut National de la Santé et de la Recherche Médicale U753, Institut Gustave Roussy, Villejuif, France
    Cancer Res 67:7028-36. 2007
    ..These data indicate that the pVax1/pet-neu cDNA vaccine coding for a poly-ErbB-2 epitope is able to generate simultaneous ErbB-2-specific antitumor responses against dominant and cryptic multiple epitopes...